Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
64%(7 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
7
58%
Ph phase_3
3
25%
Ph phase_2
2
17%

Phase Distribution

7

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
7(58.3%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
3(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
91.7%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (58.3%)
Phase 22 (16.7%)
Phase 33 (25.0%)

Trials by Status

completed1192%
terminated18%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
DRUG
Total Trials
12